Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 1137-1143, March 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Connor, B. M.
Right arrow Articles by Calvert, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Connor, B. M.
Right arrow Articles by Calvert, A. H.

Human Lymphoblastoid Cells with Acquired Resistance to C2-Desamino-C2-methyl-N10-propargyl-5,8-dideazafolic Acid: A Novel Folate-based Thymidylate Synthase Inhibitor1

Brigid M. O'Connor2, Ann L. Jackman, Philip H. Crossley, Sarah E. Freemantle3, John Lunec3 and A. Hilary Calvert3

Institute of Cancer Research, Clinical Pharmacology Group, Drug Development Section, Belmont, Sutton, Surrey [B. M. O'C., A. L. J., S. E. F., A. H. C.], Imperial College, London [P. H. C.], and University of Newcastle upon Tyne, Newcastle upon Tyne [J. L.], England

We describe the characterization of human lymphoblastoid cell lines with acquired resistance (>20,000-fold) to a novel folate-based thymidylate synthase (TS) (EC 2.1.1.45) inhibitor, C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI198583). This acquired resistance was associated with a 64-fold amplification of the TS gene, a similar elevation in the corresponding mRNA, and an ~200-fold increase in both TS activity and TS protein. This amplification was maintained when the cells were grown in the absence of the selective agent, ICI198583, for 340 generations. TS isolated from one of the resistant cell lines, W1-L2:C1, displayed inhibition kinetic parameters similar to those of TS isolated from the parent W1-L2 cell line. It thus appears unlikely that resistance is due to an altered TS enzyme having a lower affinity for ICI198583. The resistant cell line, W1-L2:C1, was cross-resistant to other folate-based TS inhibitors but was as sensitive as the parent cell line, W1-L2, to 5-fluorodeoxyuridine. The W1-L2:C1 cell line was collaterally sensitive to the classical dihydrofolate reductase (EC 1.5.1.3) inhibitor methotrexate as well as to the lipophilic dihydrofolate reductase inhibitors metoprine and 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline glucuronic acid salt (also called trimetrexate). When the W1-L2 and W1-L2:C1 cell lines were exposed to 1 µM ICI198583 for 24 h they accumulated the same concentration of total cellular ICI198583 polyglutamates depite the fact that the latter cell line accumulated a 300-fold greater concentration of ICI198583 monoglutamate. As polyglutamates, the tetra- and pentaglutamate forms predominated in the W1-L2 cell line, whereas the diglutamate form predominated in the W1-L2:C1 cell line, with few higher polyglutamates being detected. The lack of tri- and higher polyglutamates of ICI198583 (i.e., the more active species) in the W1-L2:C1 cell line may also contribute to the observed resistance. These findings may have important implications in light of the rapid onset of resistance to antifolates in the clinic.

1 This work was supported by grants from the Cancer Research Campaign and Medical Research Council of the United Kingdom.

2 To whom requests for reprints should be addressed, at the Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany, NY 12201.

3 Present address: University of Newcastle upon Tyne, Department of Clinical Oncology, Framlington Place, Newcastle upon Tyne NE2 4HH, England.

Received 6/10/91. Accepted 12/11/91.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. J. Welsh, J. Titley, L. Brunton, M. Valenti, P. Monaghan, A. L. Jackman, and G. W. Aherne
Comparison of Thymidylate Synthase (TS) Protein Up-Regulation after Exposure to TS Inhibitors in Normal and Tumor Cell Lines and Tissues
Clin. Cancer Res., June 1, 2000; 6(6): 2538 - 2546.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.